^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CLIP1 (CAP-Gly Domain Containing Linker Protein 1)

    i
    Other names: CLIP1, CAP-Gly Domain Containing Linker Protein 1, CLIP-170, CYLN1, Restin (Reed-Steinberg Cell-Expressed Intermediate Filament-Associated Protein), CAP-Gly Domain-Containing Linker Protein 1, Cytoplasmic Linker Protein 170 Alpha-2, Cytoplasmic Linker Protein 1, CLIP170, Restin, CLIP, RSN, Reed-Sternberg Intermediate Filament-Associated Protein, CAP-GLY Domain Containing Linker Protein 1, Cytoplasmic Linker Protein CLIP-170
    2ms
    Microtubule-based cup-like structures appear during microparticle uptake in U2OS cells cultured on different substrate types. (PubMed, Tissue Cell)
    In conclusion, our findings demonstrate that substrate type modulates multiple aspects of U2OS cell behavior, including morphology, cytoskeletal arrangement, mechanical properties, and microparticle uptake. These results underscore the mechanosensitive nature of osteosarcoma cells and highlight novel roles for microtubule cup-like structures and MAPs, particularly IQGAP1 in cellular uptake mechanisms.
    Preclinical • Journal
    |
    CLIP1 (CAP-Gly Domain Containing Linker Protein 1) • MARK2 (Microtubule Affinity Regulating Kinase 2) • IQGAP1 (IQ Motif Containing GTPase Activating Protein 1)
    3ms
    Human Fidgetin Modulates Cell Migration and EMT in Breast Cancer Cells. (PubMed, Cell Biol Int)
    Our findings indicate that microtubule regulation by fidgetin influences cancer cell motility by altering the expression of EMT-promoting transcription factors and modulating the accumulation of focal adhesion and EB1 proteins. These results suggest that fidgetin could be a promising therapeutic target in cancer.
    Journal
    |
    VIM (Vimentin) • CDH2 (Cadherin 2) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1) • SNAI2 (Snail Family Transcriptional Repressor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
    7ms
    Novel kinase-activating genetic events in non-small cell lung carcinomas. (PubMed, Explor Target Antitumor Ther)
    ROS1, LTK, and FGFR4 high-level overexpression was observed in 1 out of 89 tumors each. This study demonstrates the scarcity of yet unknown kinase-activating alterations in NSCLCs.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • FGFR4 (Fibroblast growth factor receptor 4) • LTK (Leukocyte Receptor Tyrosine Kinase) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1) • KAT6B (Lysine Acetyltransferase 6B) • VMP1 (Vacuole Membrane Protein 1)
    1year
    CLIP170 enhancing FOSL1 expression via attenuating ubiquitin-mediated degradation of β-catenin drives renal cell carcinoma progression. (PubMed, Cell Mol Life Sci)
    This study highlights the crucial role of CLIP170 in promoting FOSL1 expression by preventing β-catenin ubiquitination and degradation, thus promoting RCC tumor progression. It suggests the CLIP170/β-catenin/FOSL1 axis as a potential therapeutic target for RCC treatment.
    Journal
    |
    FOSL1 (FOS Like 1) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1)
    |
    FOSL1 expression
    over1year
    Multi-Omics Analysis of Primary Prostate Cancer Datasets Reveals Novel Biomarkers. (PubMed, Biochem Genet)
    Although the changes in the expression levels of miR-7-5p and CAMKK2, TMEM97, and CLIP1 in the two cell lines used in our study were not consistent with the significant expression differences observed in the meta-analysis, our meta-analysis results would be promising in human prostate tissue or different human tumor cell line studies. This highlights the importance of our meta-analysis results in prostate cancer biomarker research, given the difficulty of experimental validation of our large-scale data meta-analysis results using a specific cell line.
    Journal
    |
    MIR7 (MicroRNA 7) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1)
    over1year
    Spitz Melanoma With SLC20A1::ALK Fusion: A Novel Fusion Previously Undescribed in Spitz Melanocytic Neoplasm. (PubMed, Am J Dermatopathol)
    Here, we present a case of Spitz melanoma harboring SLC20A1::ALK fusion, highlighting a novel fusion transcript not previously reported in Spitz melanocytic neoplasms, including Spitz melanomas. In addition, the tumor exhibits multiple aberrant chromosomal alterations characteristic of melanoma, along with a somatic mutation in GRM3.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • TPM3 (Tropomyosin 3) • DCTN1 (Dynactin Subunit 1) • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1) • MLPH (Melanophilin)
    over1year
    ALK-rearranged mesenchymal neoplasms: a clinicopathological and molecular study of eight additional cases of an emerging group of tyrosine kinase fusion mesenchymal tumours. (PubMed, J Clin Pathol)
    Our study expands the clinicopathological and molecular spectrum of ALK-rearranged mesenchymal neoplasms.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • CD34 (CD34 molecule) • MMP2 (Matrix metallopeptidase 2) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1) • PLEKHH2 (Pleckstrin Homology, MyTH4 And FERM Domain Containing H2)
    almost2years
    Spitz melanocytic neoplasms with MLPH::ALK fusions: Report of two cases with previously unreported features and literature review. (PubMed, J Cutan Pathol)
    In this report, we present two additional cases, including a previously unreported instance of Spitz melanoma, contributing to the expanding knowledge on ALK-fused Spitz melanocytic neoplasms. In addition, we provide a comprehensive review of the clinical, histopathologic, and molecular features observed in documented cases with this novel fusion.
    Clinical • Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • TPM3 (Tropomyosin 3) • DCTN1 (Dynactin Subunit 1) • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1) • EHBP1 (EH Domain Binding Protein 1) • MLPH (Melanophilin) • RAB27A (RAB27A, Member RAS Oncogene Family)
    |
    ALK fusion • NPM1-ALK fusion
    almost2years
    CLIP170 inhibits the metastasis and EMT of papillary thyroid cancer through the TGF-β pathway. (PubMed, Med Oncol)
    Remarkably, the TGF-β inhibitor LY2157299 effectively countered TGF-β activity and significantly reversed tumor metastasis and EMT induced by CLIP170 knockdown. In summary, these findings collectively propose CLIP170 as a promising therapeutic target to mitigate metastatic tendencies in PTC.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1)
    |
    galunisertib (LY2157299)
    almost2years
    RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma-like mesenchymal tumors. (PubMed, J Pathol)
    Our findings document that RAF1 gene rearrangements represent a recurrent event in ETV6::NTRK3-negative IFS/CMN and provide a rationale for the use of inhibitors directed to suppress MAPK and PI3K-AKT signaling in these cancers.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • GOLGA4 (Golgin A4) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1)
    |
    NTRK3 fusion
    almost2years
    LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion. (PubMed, Commun Biol)
    In vitro and in vivo analyses demonstrate that gilteritinib can overcome the L650F-mediated resistance to lorlatinib. In silico analysis suggests that introduction of the L650F mutation may attenuate lorlatinib-LTK binding. Our study provides preclinical evaluations of potential on-target resistance mutations to lorlatinib, and a novel strategy to overcome the resistance.
    Journal
    |
    CLIP1 (CAP-Gly Domain Containing Linker Protein 1)
    |
    ALK mutation
    |
    Lorbrena (lorlatinib) • Xospata (gilteritinib)
    over2years
    Characterization of the genomic alterations in poorly differentiated thyroid cancer. (PubMed, Sci Rep)
    Through the association analysis of somatic mutations and the characteristics of clinical pathology from patients with PDTC, the somatic mutations of ABCA12, CLIP1, and ATP13A3 were significantly associated with a vascular invasion phenotype. By providing molecular genetic insight on PDTC, this study may contribute to the discovery of novel therapeutic target candidates.
    Journal
    |
    MAP2K2 (Mitogen-activated protein kinase kinase 2) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1) • ABCA1 (ATP Binding Cassette Subfamily A Member 1)